The Experts below are selected from a list of 207 Experts worldwide ranked by ideXlab platform
John E. Tavis - One of the best experts on this subject based on the ideXlab platform.
-
A mid-tHrougHput HBV replication inHibition assay capable of detecting Ribonuclease H inHibitors
Journal of virological methods, 2021Co-Authors: Tiffany C. Edwards, Nathan L. Ponzar, John E. TavisAbstract:Abstract THe Hepatitis B virus (HBV) Ribonuclease H (RNaseH) is a promising but unexploited drug target. InHibiting tHe RNaseH blocks viral reverse transcription by truncating tHe minus-polarity DNA strand, causing accumulation of RNA:DNA Heteroduplexes, and abrogating plus-polarity DNA syntHesis. Screening for RNaseH inHibitors is complicated by tHe presence of tHe minus-polarity DNA strand even wHen replication is fully inHibited because tHis residual DNA can be detected by standard screening assays tHat measure reduction in HBV DNA accumulation. We previously developed a strand-preferential qPCR assay tHat detects RNaseH replication inHibitors by measuring preferential suppression of tHe viral plus-polarity DNA strand. However, tHis assay employed cells grown in 6- or 12-well plates and Hence was of very low tHrougHput. Here, we adapted tHe assay to a 96-well format and conducted a proof-of-principle screen of 727 compounds. THe newly developed assay is a valuable tool for anti-HBV drug discovery, particularly wHen screening for RNaseH inHibitors.
-
inHibition of Hbv replication by n Hydroxyisoquinolinedione and n Hydroxypyridinedione Ribonuclease H inHibitors
Antiviral Research, 2019Co-Authors: Tiffany C. Edwards, Nagraj Mani, Bruce D Dorsey, Ramesh Kakarla, Rene Rijnbrand, Michael J Sofia, John E. TavisAbstract:Abstract We recently developed a screening system capable of identifying and evaluating inHibitors of tHe Hepatitis B virus (HBV) Ribonuclease H (RNaseH), wHicH is tHe only HBV enzyme not targeted by current anti-HBV tHerapies. InHibiting tHe HBV RNaseH blocks syntHesis of tHe positive-polarity DNA strand, causing early termination of negative-polarity DNA syntHesis and accumulation of RNA:DNA Heteroduplexes. We previously reported inHibition of HBV replication by N-Hydroxyisoquinolinediones (HID) and N-Hydroxypyridinediones (HPD) in Human Hepatoma cells. Here, we report results from our ongoing efforts to develop more potent anti-HBV RNaseH inHibitors in tHe HID/HPD compound classes. We syntHesized and screened additional HIDs and HPDs for preferential suppression of positive-polarity DNA in cells replicating HBV. THree of seven new HIDs inHibited HBV replication, However, tHe tHerapeutic indexes (TI = CC50/EC50) did not improve over wHat we previously reported. All nine of tHe HPDs inHibited HBV replication witH EC50s ranging from 110 nM to 4 μM. Cellular cytotoxicity was evaluated by four assays and CC50s ranged from 15 to >100 μM. THe best compounds Have a calculated TI of >300, wHicH is a 16-fold improvement over tHe primary HPD Hit. THese studies indicate tHat tHe HPD compound class Holds potential for antiviral discovery.
-
CHemical ApproacHes to InHibiting tHe Hepatitis B Virus Ribonuclease H.
ACS infectious diseases, 2018Co-Authors: John E. Tavis, Grigoris Zoidis, Marvin J. Meyers, Ryan P. MurelliAbstract:Hepatitis B virus (HBV) cHronically infects >250 million people and kills nearly a million annually, and current antivirals cannot clear tHe infection or adequately suppress disease. THe virus replicates by reverse transcription, and tHe dominant antiviral drugs are nucleos(t)ide analogs tHat target tHe viral reverse transcriptase. We are developing antivirals targeting tHe otHer essential viral enzymatic activity, tHe Ribonuclease H (RNaseH). HBV RNaseH inHibitors witH efficacies in tHe low micromolar to nanomolar range against viral replication in culture Have been identified in tHe α-Hydroxytropolone and Hydroxyimide cHemotypes. Here, we review tHe promise of RNaseH inHibitors, tHeir current structure–activity relationsHips, and cHallenges to optimizing tHe inHibitors into leads for clinical assessment.
-
efficacy and cytotoxicity in cell culture of novel α Hydroxytropolone inHibitors of Hepatitis b virus Ribonuclease H
Antiviral Research, 2017Co-Authors: Elena Lomonosova, Ryan P. Murelli, Jil Daw, Aswin K Garimallaprabhakaran, Nana B Agyemang, Yashkumar Ashani, John E. TavisAbstract:Abstract CHronic Hepatitis B virus (HBV) infection is a major worldwide public HealtH problem. Current direct-acting anti-HBV drugs target tHe HBV DNA polymerase activity, but tHe equally essential viral Ribonuclease H (RNaseH) activity is unexploited as a drug target. Previously, we reported tHat α–Hydroxytropolone compounds can inHibit tHe HBV RNaseH and block viral replication. Subsequently, we found tHat our biocHemical RNaseH assay underreports efficacy of tHe α-Hydroxytropolones against HBV replication. THerefore, we conducted a structure-activity analysis of 59 troponoids against HBV replication in cell culture. THese studies revealed tHat antiviral efficacy is diminisHed by larger substitutions on tHe tropolone ring, identified key components in tHe substitutions needed for HigH efficacy, and revealed tHat cytotoxicity correlates witH increased lipopHilicity of tHe α-Hydroxytropolones. THese data provide key guidance for furtHer optimization of tHe α-Hydroxytropolone scaffold as novel HBV RNaseH inHibitors.
-
tHe Hepatitis b virus Ribonuclease H as a drug target
Antiviral Research, 2015Co-Authors: John E. Tavis, Elena LomonosovaAbstract:Abstract CHronic Hepatitis B virus (HBV) infection is a leading cause of Hepatitis, liver failure, and Hepatocellular carcinoma. An outstanding vaccine is available; However, tHe number of infections remains HigH. Current anti-HBV treatments witH interferon α and nucleos(t)ide analogs clear tHe infection in only a small minority of patients, and eitHer induce serious side-effects or are of very long duration. HBV is a small, enveloped DNA virus tHat replicates by reverse transcription via an RNA intermediate. THe HBV Ribonuclease H (RNaseH) is essential for viral replication, but it Has not been exploited as a drug target. Recent low-tHrougHput screening of compound classes witH anti-Human Immunodeficiency Virus RNaseH activity led to identification of HBV RNaseH inHibitors in tHree different cHemical families tHat block HBV replication. THese inHibitors are promising candidates for development into new anti-HBV drugs. THe RNaseH inHibitors may Help improve treatment efficacy enougH to clear tHe virus from tHe liver wHen used in combination witH existing anti-HBV drugs and/or witH otHer novel inHibitors under development. THis article forms part of a symposium in Antiviral ResearcH on “An unfinisHed story: from tHe discovery of tHe Australia antigen to tHe development of new curative tHerapies for Hepatitis B.”
Ryan P. Murelli - One of the best experts on this subject based on the ideXlab platform.
-
CHemical ApproacHes to InHibiting tHe Hepatitis B Virus Ribonuclease H.
ACS infectious diseases, 2018Co-Authors: John E. Tavis, Grigoris Zoidis, Marvin J. Meyers, Ryan P. MurelliAbstract:Hepatitis B virus (HBV) cHronically infects >250 million people and kills nearly a million annually, and current antivirals cannot clear tHe infection or adequately suppress disease. THe virus replicates by reverse transcription, and tHe dominant antiviral drugs are nucleos(t)ide analogs tHat target tHe viral reverse transcriptase. We are developing antivirals targeting tHe otHer essential viral enzymatic activity, tHe Ribonuclease H (RNaseH). HBV RNaseH inHibitors witH efficacies in tHe low micromolar to nanomolar range against viral replication in culture Have been identified in tHe α-Hydroxytropolone and Hydroxyimide cHemotypes. Here, we review tHe promise of RNaseH inHibitors, tHeir current structure–activity relationsHips, and cHallenges to optimizing tHe inHibitors into leads for clinical assessment.
-
Efficacy of Hepatitis B virus Ribonuclease H inHibitors, a new class of replication antagonists, in FRG Human liver cHimeric mice
Antiviral research, 2017Co-Authors: Kelly R. Long, Elena Lomonosova, Nathan L. Ponzar, Juan A. Villa, Erin Touchette, Stephen R. Rapp, R. Matt Liley, Ryan P. Murelli, Alexandre GrigoryanAbstract:CHronic Hepatitis B virus infection cannot be cured by current tHerapies, so new treatments are urgently needed. We recently identified novel inHibitors of tHe Hepatitis B virus Ribonuclease H tHat suppress viral replication in cell culture. Here, we employed immunodeficient FRG KO mice wHose livers Had been engrafted witH primary Human Hepatocytes to ask wHetHer Ribonuclease H inHibitors can suppress Hepatitis B virus replication in vivo. Humanized FRG KO mice infected witH Hepatitis B virus were treated for two weeks witH tHe Ribonuclease H inHibitors #110, an α-Hydroxytropolone, and #208, an N-Hydroxypyridinedione. Hepatitis B virus viral titers and S and e antigen plasma levels were measured. Treatment witH #110 and #208 caused significant reductions in plasma viremia witHout affecting Hepatitis B virus S or e antigen levels, and viral titers rebounded following treatment cessation. THis is tHe expected pattern for inHibitors of viral DNA syntHesis. Compound #208 suppressed viral titers of botH Hepatitis B virus genotype A and C isolates. THese data indicate tHat Hepatitis B virus replication can be suppressed during infection in an animal by inHibiting tHe viral Ribonuclease H, validating tHe Ribonuclease H as a novel target for antiviral drug development.
-
efficacy and cytotoxicity in cell culture of novel α Hydroxytropolone inHibitors of Hepatitis b virus Ribonuclease H
Antiviral Research, 2017Co-Authors: Elena Lomonosova, Ryan P. Murelli, Jil Daw, Aswin K Garimallaprabhakaran, Nana B Agyemang, Yashkumar Ashani, John E. TavisAbstract:Abstract CHronic Hepatitis B virus (HBV) infection is a major worldwide public HealtH problem. Current direct-acting anti-HBV drugs target tHe HBV DNA polymerase activity, but tHe equally essential viral Ribonuclease H (RNaseH) activity is unexploited as a drug target. Previously, we reported tHat α–Hydroxytropolone compounds can inHibit tHe HBV RNaseH and block viral replication. Subsequently, we found tHat our biocHemical RNaseH assay underreports efficacy of tHe α-Hydroxytropolones against HBV replication. THerefore, we conducted a structure-activity analysis of 59 troponoids against HBV replication in cell culture. THese studies revealed tHat antiviral efficacy is diminisHed by larger substitutions on tHe tropolone ring, identified key components in tHe substitutions needed for HigH efficacy, and revealed tHat cytotoxicity correlates witH increased lipopHilicity of tHe α-Hydroxytropolones. THese data provide key guidance for furtHer optimization of tHe α-Hydroxytropolone scaffold as novel HBV RNaseH inHibitors.
-
SyntHetic α-Hydroxytropolones as inHibitors of HIV reverse transcriptase Ribonuclease H activity
MedChemComm, 2016Co-Authors: Ryan P. Murelli, Michael P. D'erasmo, Danielle R. Hirsch, Christine Meck, Takashi Masaoka, Jennifer A. Wilson, Baofeng Zhang, Rajat Kumar Pal, Emilio Gallicchio, John A. BeutlerAbstract:HIV reverse transcriptase-associated Ribonuclease H activity is a promising enzymatic target for drug development tHat Has not been successfully targeted in tHe clinic. WHile tHe α-Hydroxytropolone-containing natural products β-tHujaplicinol and manicol Have emerged as some of tHe most potent leads described to date, structure–function studies Have been limited to tHe natural products and semi-syntHetic derivatives of manicol. THus, a library of α-Hydroxytropolones syntHesized tHrougH a convenient oxidopyrylium cycloaddition/ring-opening sequence Have been tested in in vitro and cell-based assays, and Have been analyzed using computational support. THese studies reveal new syntHetic α-Hydroxytropolones tHat, unlike tHe natural product leads tHey are derived from, demonstrate protective antiviral activity in cellular assays.
Michael A. Parniak - One of the best experts on this subject based on the ideXlab platform.
-
THe Hepatitis B Virus Ribonuclease H Is Sensitive to InHibitors of tHe Human Immunodeficiency Virus Ribonuclease H and Integrase Enzymes
PLoS pathogens, 2013Co-Authors: John E. Tavis, Marvin J. Meyers, Xiaohong Cheng, Michael Totten, Feng Cao, Eleftherios Michailidis, Rajeev Aurora, E. Jon Jacobsen, Michael A. ParniakAbstract:Nucleos(t)ide analog tHerapy blocks DNA syntHesis by tHe Hepatitis B virus (HBV) reverse transcriptase and can control tHe infection, but treatment is life-long and Has HigH costs and unpredictable long-term side effects. THe profound suppression of HBV by tHe nucleos(t)ide analogs and tHeir ability to cure some patients indicates tHat tHey can pusH HBV to tHe brink of extinction. Consequently, more patients could be cured by suppressing HBV replication furtHer using a new drug in combination witH tHe nucleos(t)ide analogs. THe HBV Ribonuclease H (RNAseH) is a logical drug target because it is tHe second of only two viral enzymes tHat are essential for viral replication, but it Has not been exploited, primarily because it is very difficult to produce active enzyme. To address tHis difficulty, we expressed HBV genotype D and H RNAseHs in E. coli and enricHed tHe enzymes by nickel-affinity cHromatograpHy. HBV RNAseH activity in tHe enricHed lysates was cHaracterized in preparation for drug screening. Twenty-one candidate HBV RNAseH inHibitors were identified using cHemical structure-activity analyses based on inHibitors of tHe HIV RNAseH and integrase. Twelve anti-RNAseH and anti-integrase compounds inHibited tHe HBV RNAseH at 10 µM, tHe best compounds Had low micromolar IC(50) values against tHe RNAseH, and one compound inHibited HBV replication in tissue culture at 10 µM. Recombinant HBV genotype D RNAseH was more sensitive to inHibition tHan genotype H. THis study demonstrates tHat recombinant HBV RNAseH suitable for low-tHrougHput antiviral drug screening Has been produced. THe HigH percentage of compounds developed against tHe HIV RNAseH and integrase tHat were active against tHe HBV RNAseH indicates tHat tHe extensive drug design efforts against tHese HIV enzymes can guide anti-HBV RNAseH drug discovery. Finally, differential inHibition of HBV genotype D and H RNAseHs indicates tHat viral genetic variability will be a factor during drug development.
-
inHibitors of Hiv 1 reverse transcriptase associated Ribonuclease H activity
Biology, 2012Co-Authors: Tatiana Ilina, Rieko Ishima, Krystal Labarge, Stefan G Sarafianos, Michael A. ParniakAbstract:HIV-1 enzyme reverse transcriptase (RT) is a major target for antiviral drug development, witH over Half of current FDA-approved tHerapeutics against HIV infection targeting tHe DNA polymerase activity of tHis enzyme. HIV-1 RT is a multifunctional enzyme tHat Has RNA and DNA dependent polymerase activity, along witH Ribonuclease H (RNase H) activity. THe latter is responsible for degradation of tHe viral genomic RNA template during first strand DNA syntHesis to allow completion of reverse transcription and tHe viral dsDNA. WHile tHe RNase H activity of RT Has been sHown to be essential for virus infectivity, all currently used drugs directed at RT inHibit tHe polymerase activity of tHe enzyme; none target RNase H. In tHe last decade, tHe increasing prevalence of HIV variants resistant to clinically used antiretrovirals Has stimulated tHe searcH for inHibitors directed at stages of HIV replication different tHan tHose targeted by current drugs. HIV RNase H is one sucH novel target and, over tHe past few years, significant progress Has been made in identifying and cHaracterizing new RNase H inHibitor pHarmacopHores. In tHis review we focus mainly on tHe most potent low micromolar potency compounds, as tHese provide logical bases for furtHer development. We also discuss wHy HIV RNase H Has been a difficult target for antiretroviral drug development.
-
interaction of Hiv 1 reverse transcriptase Ribonuclease H witH an acylHydrazone inHibitor
Chemical Biology & Drug Design, 2011Co-Authors: Qingguo Gong, Lakshmi Menon, Tatiana Ilina, Lena Miller, Michael A. Parniak, Rieko IshimaAbstract:HIV-1 reverse transcriptase (RT) is a bi-functional enzyme, Having botH DNA polymerase (RNA- and DNA-dependent) and Ribonuclease H (RNH) activities. HIV-1 RT Has been an exceptionally important target for antiretroviral tHerapeutic development, and nearly Half of tHe current clinically used antiretrovirals target RT DNA polymerase. However, no inHibitors of RT RNH are on tHe market or in preclinical development. Several drug-like small molecule inHibitors of RT RNH Have been described, but little structural information is available about tHe interactions between RT RNH and inHibitors tHat exHibit antiviral activity. In tHis report, we describe NMR studies of tHe interaction of a new RNH inHibitor, BHMP07, witH a catalytically active HIV-1 RT RNH domain fragment. We carried out solution NMR experiments to identify tHe interaction interface of BHMP07 witH tHe RNH domain fragment. CHemical sHift cHanges of backbone amide signals at different BHMP07 concentrations clearly demonstrate tHat BHMP07 mainly recognizes tHe substrate Handle region in tHe RNH fragment. Using RNH inHibition assays and RT mutants, tHe binding specificity of BHMP07 was compared witH anotHer inHibitor, diHydroxy benzoyl napHtHyl Hydrazone. Our results provide a structural cHaracterization of tHe Ribonuclease H-inHibitor interaction and are likely to be useful for furtHer improvements of tHe inHibitors.
-
Interaction of HIV-1 reverse transcriptase Ribonuclease H witH an acylHydrazone inHibitor.
Chemical Biology & Drug Design, 2010Co-Authors: Qingguo Gong, Lakshmi Menon, Tatiana Ilina, Lena Miller, Jinwoo Ahn, Michael A. Parniak, Rieko IshimaAbstract:HIV-1 reverse transcriptase is a bifunctional enzyme, Having botH DNA polymerase (RNA- and DNA-dependent) and Ribonuclease H activities. HIV-1 reverse transcriptase Has been an exceptionally important target for antiretroviral tHerapeutic development, and nearly Half of tHe current clinically used antiretrovirals target reverse transcriptase DNA polymerase. However, no inHibitors of reverse transcriptase Ribonuclease H are on tHe market or in preclinical development. Several drug-like small molecule inHibitors of reverse transcriptase Ribonuclease H Have been described, but little structural information is available about tHe interactions between reverse transcriptase Ribonuclease H and inHibitors tHat exHibit antiviral activity. In tHis report, we describe NMR studies of tHe interaction of a new Ribonuclease H inHibitor, BHMP07, witH a catalytically active HIV-1 reverse transcriptase Ribonuclease H domain fragment. We carried out solution NMR experiments to identify tHe interaction interface of BHMP07 witH tHe Ribonuclease H domain fragment. CHemical sHift cHanges of backbone amide signals at different BHMP07 concentrations clearly demonstrate tHat BHMP07 mainly recognizes tHe substrate Handle region in tHe Ribonuclease H fragment. Using Ribonuclease H inHibition assays and reverse transcriptase mutants, tHe binding specificity of BHMP07 was compared witH anotHer inHibitor, diHydroxy benzoyl napHtHyl Hydrazone. Our results provide a structural cHaracterization of tHe Ribonuclease H inHibitor interaction and are likely to be useful for furtHer improvements of tHe inHibitors.
Elena Lomonosova - One of the best experts on this subject based on the ideXlab platform.
-
Efficacy of Hepatitis B virus Ribonuclease H inHibitors, a new class of replication antagonists, in FRG Human liver cHimeric mice
Antiviral research, 2017Co-Authors: Kelly R. Long, Elena Lomonosova, Nathan L. Ponzar, Juan A. Villa, Erin Touchette, Stephen R. Rapp, R. Matt Liley, Ryan P. Murelli, Alexandre GrigoryanAbstract:CHronic Hepatitis B virus infection cannot be cured by current tHerapies, so new treatments are urgently needed. We recently identified novel inHibitors of tHe Hepatitis B virus Ribonuclease H tHat suppress viral replication in cell culture. Here, we employed immunodeficient FRG KO mice wHose livers Had been engrafted witH primary Human Hepatocytes to ask wHetHer Ribonuclease H inHibitors can suppress Hepatitis B virus replication in vivo. Humanized FRG KO mice infected witH Hepatitis B virus were treated for two weeks witH tHe Ribonuclease H inHibitors #110, an α-Hydroxytropolone, and #208, an N-Hydroxypyridinedione. Hepatitis B virus viral titers and S and e antigen plasma levels were measured. Treatment witH #110 and #208 caused significant reductions in plasma viremia witHout affecting Hepatitis B virus S or e antigen levels, and viral titers rebounded following treatment cessation. THis is tHe expected pattern for inHibitors of viral DNA syntHesis. Compound #208 suppressed viral titers of botH Hepatitis B virus genotype A and C isolates. THese data indicate tHat Hepatitis B virus replication can be suppressed during infection in an animal by inHibiting tHe viral Ribonuclease H, validating tHe Ribonuclease H as a novel target for antiviral drug development.
-
efficacy and cytotoxicity in cell culture of novel α Hydroxytropolone inHibitors of Hepatitis b virus Ribonuclease H
Antiviral Research, 2017Co-Authors: Elena Lomonosova, Ryan P. Murelli, Jil Daw, Aswin K Garimallaprabhakaran, Nana B Agyemang, Yashkumar Ashani, John E. TavisAbstract:Abstract CHronic Hepatitis B virus (HBV) infection is a major worldwide public HealtH problem. Current direct-acting anti-HBV drugs target tHe HBV DNA polymerase activity, but tHe equally essential viral Ribonuclease H (RNaseH) activity is unexploited as a drug target. Previously, we reported tHat α–Hydroxytropolone compounds can inHibit tHe HBV RNaseH and block viral replication. Subsequently, we found tHat our biocHemical RNaseH assay underreports efficacy of tHe α-Hydroxytropolones against HBV replication. THerefore, we conducted a structure-activity analysis of 59 troponoids against HBV replication in cell culture. THese studies revealed tHat antiviral efficacy is diminisHed by larger substitutions on tHe tropolone ring, identified key components in tHe substitutions needed for HigH efficacy, and revealed tHat cytotoxicity correlates witH increased lipopHilicity of tHe α-Hydroxytropolones. THese data provide key guidance for furtHer optimization of tHe α-Hydroxytropolone scaffold as novel HBV RNaseH inHibitors.
-
tHe Hepatitis b virus Ribonuclease H as a drug target
Antiviral Research, 2015Co-Authors: John E. Tavis, Elena LomonosovaAbstract:Abstract CHronic Hepatitis B virus (HBV) infection is a leading cause of Hepatitis, liver failure, and Hepatocellular carcinoma. An outstanding vaccine is available; However, tHe number of infections remains HigH. Current anti-HBV treatments witH interferon α and nucleos(t)ide analogs clear tHe infection in only a small minority of patients, and eitHer induce serious side-effects or are of very long duration. HBV is a small, enveloped DNA virus tHat replicates by reverse transcription via an RNA intermediate. THe HBV Ribonuclease H (RNaseH) is essential for viral replication, but it Has not been exploited as a drug target. Recent low-tHrougHput screening of compound classes witH anti-Human Immunodeficiency Virus RNaseH activity led to identification of HBV RNaseH inHibitors in tHree different cHemical families tHat block HBV replication. THese inHibitors are promising candidates for development into new anti-HBV drugs. THe RNaseH inHibitors may Help improve treatment efficacy enougH to clear tHe virus from tHe liver wHen used in combination witH existing anti-HBV drugs and/or witH otHer novel inHibitors under development. THis article forms part of a symposium in Antiviral ResearcH on “An unfinisHed story: from tHe discovery of tHe Australia antigen to tHe development of new curative tHerapies for Hepatitis B.”
Morio Ikehara - One of the best experts on this subject based on the ideXlab platform.
-
Functions and structures of Ribonuclease H enzymes.
Sub-cellular biochemistry, 1995Co-Authors: Shigenori Kanaya, Morio IkeharaAbstract:Ribonuclease H* (RNase H, EC 3.1.26.4) is an endonuclease tHat specifically Hydrolyzes an RNA Hybridized to a complementary DNA to produce an oli-goribonucleotide witH 5′-pHospHate and 3′-Hydroxyl groups (Fig. 1). It requires divalent cations, sucH as Mg2+ and Mn2+, for activity. THe enzyme was first isolated from calf tHymus (Stein and Hausen, 1969; Hausen and Stein, 1970). Since tHen, tHe enzyme Has been sHown to be present in viruses, pHages, and various organisms from EscHericHia coli to Human (CroucH and Dirksen, 1982; Wintersberger, 1990).
-
Structural models of Ribonuclease H domains in reverse transcriptases from retroviruses.
Nucleic acids research, 1991Co-Authors: Haruki Nakamura, Kosuke Morikawa, Katsuo Katayanagi, Morio IkeharaAbstract:Tertiary models of Ribonuclease H (RNase H) domains in reverse transcriptases (RTs) from Moloney murine leukemia virus (MuLV) and Human immunodeficiency virus (HIV-1) were built based upon tHe X-ray structure of RNase H from EscHericHia coli (E. coli RNase H). In two models of RT-RNase H domains, not only active site residues but also residues, wHicH construct a HydropHobic core and Hydrogen bonds, are located in tHe same positions as tHose of E. coli RNase H. THe wHole backbone structure and tHe electrostatic molecular surface of MuLV RT-RNase H model are similar to tHose of E. coli RNase H. On tHe contrary, HIV-1 RT-RNase H model lacks tHe tHird Helix and tHe following loop, resulting no positive cHarge clusters around tHe Hybrid recognition site. Referring tHe complex models of RTs witH tHeir substrate Hybrid, tHe interaction between DNA-polymerase and RNase H domains in RTs was discussed.
-
Stabilization of EscHericHia coli Ribonuclease H by introduction of an artificial disulfide bond.
The Journal of biological chemistry, 1991Co-Authors: Shigenori Kanaya, Kosuke Morikawa, C Katsuda, S Kimura, Takahisa Nakai, Eiichi Kitakuni, Haruki Nakamura, Katsuo Katayanagi, Morio IkeharaAbstract:Abstract To examine tHe effect of tHe introduction of a disulfide bond on tHe stability of EscHericHia coli Ribonuclease H, a disulfide bond was engineered between Cys13, wHicH is present in tHe wild-type enzyme, and Cys44, wHicH is substituted for Asn44 by site-directed mutagenesis. THe disulfide bond was only formed between tHese residues upon oxidation in vitro witH redox buffer. THe conformational and tHermal stabilities were estimated from tHe guanidine HydrocHloride and tHermal denaturation curves, respectively. THe oxidized (cross-linked) mutant enzyme sHowed a Tm of 62.3 degrees C, wHicH was 11.8 degrees C HigHer tHan tHat observed for tHe wild-type enzyme. THe free energy cHange of unfolding in tHe absence of denaturant, delta G[H2O], and tHe mid-point of tHe denaturation curve, [D]1/2, of tHe oxidized mutant enzyme were also increased by 2.1-2.8 kcal/mol and 0.36-0.48 M, respectively. Introduction of a disulfide bond tHus greatly enHanced botH tHe tHermal and conformational stabilities of tHe enzyme. In addition, kinetic analyses for tHe enzymatic activities of mutant enzymes suggest tHat THr43 and Asn44 are involved in tHe substrate-binding site of tHe enzyme.